436 related articles for article (PubMed ID: 29867235)
21. Elicitation of Neutralizing Antibody Responses to HIV-1 Immunization with Nanoparticle Vaccine Platforms.
Murji AA; Qin JS; Hermanus T; Morris L; Georgiev IS
Viruses; 2021 Jul; 13(7):. PubMed ID: 34372503
[TBL] [Abstract][Full Text] [Related]
22. Stabilized trimeric peptide immunogens of the complete HIV-1 gp41 N-heptad repeat and their use as HIV-1 vaccine candidates.
Wu C; Raheem IT; Nahas DD; Citron M; Kim PS; Montefiori DC; Ottinger EA; Hepler RW; Hrin R; Patel SB; Soisson SM; Joyce JG
Proc Natl Acad Sci U S A; 2024 May; 121(22):e2317230121. PubMed ID: 38768344
[TBL] [Abstract][Full Text] [Related]
23. Structurally related but genetically unrelated antibody lineages converge on an immunodominant HIV-1 Env neutralizing determinant following trimer immunization.
Aljedani SS; Liban TJ; Tran K; Phad G; Singh S; Dubrovskaya V; Pushparaj P; Martinez-Murillo P; Rodarte J; Mileant A; Mangala Prasad V; Kinzelman R; O'Dell S; Mascola JR; Lee KK; Karlsson Hedestam GB; Wyatt RT; Pancera M
PLoS Pathog; 2021 Sep; 17(9):e1009543. PubMed ID: 34559844
[TBL] [Abstract][Full Text] [Related]
24. Cross-Linking of a CD4-Mimetic Miniprotein with HIV-1 Env gp140 Alters Kinetics and Specificities of Antibody Responses against HIV-1 Env in Macaques.
Shen X; Bogers WM; Yates NL; Ferrari G; Dey AK; Williams WT; Jaeger FH; Wiehe K; Sawant S; Alam SM; LaBranche CC; Montefiori DC; Martin L; Srivastava I; Heeney J; Barnett SW; Tomaras GD
J Virol; 2017 Oct; 91(19):. PubMed ID: 28490585
[TBL] [Abstract][Full Text] [Related]
25. The first hypervariable region of the gp120 Env glycoprotein defines the neutralizing susceptibility of heterologous human immunodeficiency virus type 1 isolates to neutralizing antibodies elicited by the SF162gp140 immunogen.
Ching LK; Vlachogiannis G; Bosch KA; Stamatatos L
J Virol; 2008 Jan; 82(2):949-56. PubMed ID: 18003732
[TBL] [Abstract][Full Text] [Related]
26. Immunogenic Display of Purified Chemically Cross-Linked HIV-1 Spikes.
Leaman DP; Lee JH; Ward AB; Zwick MB
J Virol; 2015 Jul; 89(13):6725-45. PubMed ID: 25878116
[TBL] [Abstract][Full Text] [Related]
27. Epitopes for neutralizing antibodies induced by HIV-1 envelope glycoprotein BG505 SOSIP trimers in rabbits and macaques.
Klasse PJ; Ketas TJ; Cottrell CA; Ozorowski G; Debnath G; Camara D; Francomano E; Pugach P; Ringe RP; LaBranche CC; van Gils MJ; Bricault CA; Barouch DH; Crotty S; Silvestri G; Kasturi S; Pulendran B; Wilson IA; Montefiori DC; Sanders RW; Ward AB; Moore JP
PLoS Pathog; 2018 Feb; 14(2):e1006913. PubMed ID: 29474444
[TBL] [Abstract][Full Text] [Related]
28. Vaccine Induction of Heterologous Tier 2 HIV-1 Neutralizing Antibodies in Animal Models.
Saunders KO; Verkoczy LK; Jiang C; Zhang J; Parks R; Chen H; Housman M; Bouton-Verville H; Shen X; Trama AM; Scearce R; Sutherland L; Santra S; Newman A; Eaton A; Xu K; Georgiev IS; Joyce MG; Tomaras GD; Bonsignori M; Reed SG; Salazar A; Mascola JR; Moody MA; Cain DW; Centlivre M; Zurawski S; Zurawski G; Erickson HP; Kwong PD; Alam SM; Levy Y; Montefiori DC; Haynes BF
Cell Rep; 2017 Dec; 21(13):3681-3690. PubMed ID: 29281818
[TBL] [Abstract][Full Text] [Related]
29. Elicitation of neutralizing antibodies directed against CD4-induced epitope(s) using a CD4 mimetic cross-linked to a HIV-1 envelope glycoprotein.
Dey AK; Burke B; Sun Y; Sirokman K; Nandi A; Hartog K; Lian Y; Geonnotti AR; Montefiori D; Franti M; Martin G; Carfi A; Kessler P; Martin L; Srivastava IK; Barnett SW
PLoS One; 2012; 7(1):e30233. PubMed ID: 22291921
[TBL] [Abstract][Full Text] [Related]
30. Antibodies Elicited by Multiple Envelope Glycoprotein Immunogens in Primates Neutralize Primary Human Immunodeficiency Viruses (HIV-1) Sensitized by CD4-Mimetic Compounds.
Madani N; Princiotto AM; Easterhoff D; Bradley T; Luo K; Williams WB; Liao HX; Moody MA; Phad GE; Vázquez Bernat N; Melillo B; Santra S; Smith AB; Karlsson Hedestam GB; Haynes B; Sodroski J
J Virol; 2016 May; 90(10):5031-5046. PubMed ID: 26962221
[TBL] [Abstract][Full Text] [Related]
31. Vaccination with Glycan-Modified HIV NFL Envelope Trimer-Liposomes Elicits Broadly Neutralizing Antibodies to Multiple Sites of Vulnerability.
Dubrovskaya V; Tran K; Ozorowski G; Guenaga J; Wilson R; Bale S; Cottrell CA; Turner HL; Seabright G; O'Dell S; Torres JL; Yang L; Feng Y; Leaman DP; Vázquez Bernat N; Liban T; Louder M; McKee K; Bailer RT; Movsesyan A; Doria-Rose NA; Pancera M; Karlsson Hedestam GB; Zwick MB; Crispin M; Mascola JR; Ward AB; Wyatt RT
Immunity; 2019 Nov; 51(5):915-929.e7. PubMed ID: 31732167
[TBL] [Abstract][Full Text] [Related]
32. Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding Site.
Crooks ET; Tong T; Chakrabarti B; Narayan K; Georgiev IS; Menis S; Huang X; Kulp D; Osawa K; Muranaka J; Stewart-Jones G; Destefano J; O'Dell S; LaBranche C; Robinson JE; Montefiori DC; McKee K; Du SX; Doria-Rose N; Kwong PD; Mascola JR; Zhu P; Schief WR; Wyatt RT; Whalen RG; Binley JM
PLoS Pathog; 2015 May; 11(5):e1004932. PubMed ID: 26023780
[TBL] [Abstract][Full Text] [Related]
33. HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design.
Bricault CA; Yusim K; Seaman MS; Yoon H; Theiler J; Giorgi EE; Wagh K; Theiler M; Hraber P; Macke JP; Kreider EF; Learn GH; Hahn BH; Scheid JF; Kovacs JM; Shields JL; Lavine CL; Ghantous F; Rist M; Bayne MG; Neubauer GH; McMahan K; Peng H; Chéneau C; Jones JJ; Zeng J; Ochsenbauer C; Nkolola JP; Stephenson KE; Chen B; Gnanakaran S; Bonsignori M; Williams LD; Haynes BF; Doria-Rose N; Mascola JR; Montefiori DC; Barouch DH; Korber B
Cell Host Microbe; 2019 Jan; 25(1):59-72.e8. PubMed ID: 30629920
[TBL] [Abstract][Full Text] [Related]
34. Diverse recombinant HIV-1 Envs fail to activate B cells expressing the germline B cell receptors of the broadly neutralizing anti-HIV-1 antibodies PG9 and 447-52D.
McGuire AT; Glenn JA; Lippy A; Stamatatos L
J Virol; 2014 Mar; 88(5):2645-57. PubMed ID: 24352455
[TBL] [Abstract][Full Text] [Related]
35. Achieving Potent Autologous Neutralizing Antibody Responses against Tier 2 HIV-1 Viruses by Strategic Selection of Envelope Immunogens.
Hessell AJ; Malherbe DC; Pissani F; McBurney S; Krebs SJ; Gomes M; Pandey S; Sutton WF; Burwitz BJ; Gray M; Robins H; Park BS; Sacha JB; LaBranche CC; Fuller DH; Montefiori DC; Stamatatos L; Sather DN; Haigwood NL
J Immunol; 2016 Apr; 196(7):3064-78. PubMed ID: 26944928
[TBL] [Abstract][Full Text] [Related]
36. Stabilizing HIV-1 envelope glycoprotein trimers to induce neutralizing antibodies.
Torrents de la Peña A; Sanders RW
Retrovirology; 2018 Sep; 15(1):63. PubMed ID: 30208933
[TBL] [Abstract][Full Text] [Related]
37. Antibody responses induced by SHIV infection are more focused than those induced by soluble native HIV-1 envelope trimers in non-human primates.
van Schooten J; van Haaren MM; Li H; McCoy LE; Havenar-Daughton C; Cottrell CA; Burger JA; van der Woude P; Helgers LC; Tomris I; Labranche CC; Montefiori DC; Ward AB; Burton DR; Moore JP; Sanders RW; Crotty S; Shaw GM; van Gils MJ
PLoS Pathog; 2021 Aug; 17(8):e1009736. PubMed ID: 34432859
[TBL] [Abstract][Full Text] [Related]
38. Characterization and Implementation of a Diverse Simian Immunodeficiency Virus SIVsm Envelope Panel in the Assessment of Neutralizing Antibody Breadth Elicited in Rhesus Macaques by Multimodal Vaccines Expressing the SIVmac239 Envelope.
Kilgore KM; Murphy MK; Burton SL; Wetzel KS; Smith SA; Xiao P; Reddy S; Francella N; Sodora DL; Silvestri G; Cole KS; Villinger F; Robinson JE; Pulendran B; Hunter E; Collman RG; Amara RR; Derdeyn CA
J Virol; 2015 Aug; 89(16):8130-51. PubMed ID: 26018167
[TBL] [Abstract][Full Text] [Related]
39. Inducing cross-clade neutralizing antibodies against HIV-1 by immunofocusing.
Humbert M; Rasmussen RA; Ong H; Kaiser FM; Hu SL; Ruprecht RM
PLoS One; 2008; 3(12):e3937. PubMed ID: 19081789
[TBL] [Abstract][Full Text] [Related]
40. Membrane bound Indian clade C HIV-1 envelope antigen induces antibodies to diverse and conserved epitopes upon DNA prime/protein boost in rabbits.
Rangasamy SP; Menon V; Dhopeshwarkar P; Pal R; Vaniambadi KS; Mahalingam S
Vaccine; 2016 May; 34(21):2444-2452. PubMed ID: 27032514
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
